20 Drugs That Got Their Start, In Part, With US Public Funding
The Trump Administration’s budget proposal aims to slash NIH funding that's critical to drug discovery and early research. Here’s a look at 20 of the 213 FDA-approved drugs that benefited from public grants, including IO pioneer Yervoy.
You may also be interested in...
Scientists Marched To Protect NIH Grants, But Where Was Pharma?
Funding from the US National Institutes of Health is a vital source for biomedical research and pharmaceutical pipelines in turn – but biopharma companies have been largely silent on the matter.
100% User Fees For US FDA? Trump Budget Revives Important Issue For Industry – But Not This Year
Trump Administration’s surprising call for increased user fees probably won’t have much impact on pending reauthorization process, but it does put on the table an important question for the biopharma industry to consider for the long term: should FDA be fully funded by user fees?
What Medarex Has To Offer At $2.4 Billion
Bristol-Myers Squibb's July 22 offer to buy Medarex for $2.4 billion seems to be a coup for the biotech. While most biotechs are struggling to raise money, Medarex enticed a suitor to pay nearly double its recent stock price